CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 195 filers reported holding CLOVIS ONCOLOGY INC in Q3 2018. The put-call ratio across all filers is 0.31 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $198,347,000 | -25.5% | 98,191 | 0.0% | 0.00% | – |
Q4 2021 | $266,096,000 | -39.2% | 98,191 | 0.0% | 0.00% | – |
Q3 2021 | $437,931,000 | -40.7% | 98,191 | -22.9% | 0.00% | – |
Q2 2021 | $738,723,000 | +36.3% | 127,366 | +65.0% | 0.00% | – |
Q1 2021 | $541,973,000 | +40.9% | 77,204 | -3.6% | 0.00% | – |
Q4 2020 | $384,571,000 | -15.4% | 80,119 | +2.7% | 0.00% | – |
Q3 2020 | $454,809,000 | -15.5% | 78,012 | -2.2% | 0.00% | – |
Q2 2020 | $538,347,000 | +143.8% | 79,755 | +42.0% | 0.00% | – |
Q3 2019 | $220,808,000 | -62.0% | 56,185 | +43.9% | 0.00% | – |
Q2 2019 | $580,629,000 | -32.1% | 39,047 | +13.3% | 0.00% | -100.0% |
Q1 2019 | $855,695,000 | +152.2% | 34,476 | +82.5% | 0.00% | – |
Q4 2018 | $339,246,000 | -89.2% | 18,889 | -82.4% | 0.00% | -100.0% |
Q3 2018 | $3,152,606,000 | -34.0% | 107,341 | +2.1% | 0.00% | -50.0% |
Q2 2018 | $4,779,033,000 | -78.5% | 105,103 | -75.0% | 0.00% | -76.5% |
Q1 2018 | $22,181,544,000 | -40.9% | 420,105 | -23.9% | 0.02% | -46.9% |
Q4 2017 | $37,541,576,000 | +21.9% | 552,082 | +47.7% | 0.03% | +14.3% |
Q3 2017 | $30,796,588,000 | +15.6% | 373,745 | +31.4% | 0.03% | +7.7% |
Q2 2017 | $26,635,955,000 | +53.8% | 284,481 | +4.6% | 0.03% | +44.4% |
Q1 2017 | $17,324,098,000 | +153061.5% | 272,092 | +6.9% | 0.02% | +38.5% |
Q4 2016 | $11,311,000 | +19.7% | 254,642 | -2.9% | 0.01% | +30.0% |
Q3 2016 | $9,453,000 | +5493.5% | 262,218 | +2033.8% | 0.01% | – |
Q2 2016 | $169,000 | -28.4% | 12,289 | 0.0% | 0.00% | – |
Q1 2016 | $236,000 | -50.0% | 12,289 | -8.9% | 0.00% | -100.0% |
Q4 2015 | $472,000 | -74.7% | 13,489 | -33.6% | 0.00% | -50.0% |
Q3 2015 | $1,868,000 | +83.3% | 20,317 | +75.1% | 0.00% | +100.0% |
Q2 2015 | $1,019,000 | +59.7% | 11,600 | +34.9% | 0.00% | 0.0% |
Q1 2015 | $638,000 | +39.0% | 8,600 | +4.9% | 0.00% | – |
Q4 2014 | $459,000 | +35.0% | 8,200 | +9.3% | 0.00% | – |
Q3 2014 | $340,000 | +9.3% | 7,500 | 0.0% | 0.00% | – |
Q2 2014 | $311,000 | -40.2% | 7,500 | 0.0% | 0.00% | -100.0% |
Q1 2014 | $520,000 | +21.5% | 7,500 | +5.6% | 0.00% | – |
Q4 2013 | $428,000 | +49.7% | 7,100 | +51.1% | 0.00% | – |
Q3 2013 | $286,000 | – | 4,700 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Palo Alto Investors LP | 3,402,781 | $231,389,000 | 9.96% |
Versant Venture Management, LLC | 101,855 | $6,926,140,000 | 7.29% |
Avoro Capital Advisors LLC | 1,102,884 | $74,996,000 | 4.86% |
Redmile Group, LLC | 1,320,027 | $89,762,000 | 3.90% |
NEXTHERA CAPITAL LP | 233,200 | $15,858,000 | 2.92% |
Iguana Healthcare Management, LLC | 60,000 | $4,080,000 | 2.66% |
HealthCor Management, L.P. | 973,840 | $66,221,000 | 2.16% |
Casdin Capital, LLC | 127,500 | $8,670,000 | 2.11% |
Prosight Management, LP | 40,000 | $2,720,000 | 2.00% |
Camber Capital Management LP | 600,000 | $40,800,000 | 2.00% |